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We showed previously that NKT cell–deficient TCR J
 
 
 
18
 
   
 
 mice are more susceptible to 
methylcholanthrene (MCA)-induced sarcomas, and that normal tumor surveillance can be 
restored by adoptive transfer of WT liver-derived NKT cells. Liver-derived NKT cells were 
used in these studies because of their relative abundance in this organ, and it was assumed 
that they were representative of NKT cells from other sites. We compared NKT cells from 
liver, thymus, and spleen for their ability to mediate rejection of the sarcoma cell line 
(MCA-1) in vivo, and found that this was a specialized function of liver-derived NKT cells. 
Furthermore, when CD4
 
 
 
 and CD4
 
 
 
 liver-derived NKT cells were administered separately, 
MCA-1 rejection was mediated primarily by the CD4
 
 
 
 fraction. Very similar results were 
achieved using the B16F10 melanoma metastasis model, which requires NKT cell stimulation 
with 
 
 
 
-galactosylceramide. The impaired ability of thymus-derived NKT cells was due, in 
part, to their production of IL-4, because tumor immunity was clearly enhanced after 
transfer of IL-4–deficient thymus-derived NKT cells. This is the first study to demonstrate 
the existence of functionally distinct NKT cell subsets in vivo and may shed light on the 
long-appreciated paradox that NKT cells function as immunosuppressive cells in some 
disease models, whereas they promote cell-mediated immunity in others.
 
NKT cells are a unique population of T cells
that mediate potent immunoregulatory roles in
vivo. Found in mice and humans, NKT cells
express a heavily biased TCR repertoire; most
cells express the TCR V
 
 
 
14-J
 
 
 
18 chain coupled
to TCR V
 
 
 
8.2, V
 
 
 
7, or V
 
 
 
2 in mice, and
TCR V
 
 
 
24-J
 
 
 
18 coupled to TCR V
 
 
 
11 in
humans (for review see reference 1). This
TCR specifically recognizes glycolipid antigens
that are presented in the context of CD1d.
The best known example of such an antigen is
 
 
 
-galactosylceramide (
 
 
 
-GalCer) (reviewed in
reference 2); however, recent studies revealed
the identify of several other glycolipid antigens
that are recognized by the NKT cell antigen
receptor, including the endogenous lysoso-
mal glycosphingolipid, isoglobotrihexosylcer-
amide (3, 4); glycolipids that are derived from
some gram-negative, LPS-negative bacteria,
including 
 
Ehrlichia
 
 and 
 
Sphingomonas
 
 (4–7);
mycobacterial phosphatidylinositol mannoside
(8); and phosphoethanolamine (9). The inter-
action between this TCR and the CD1d mol-
ecule is so critical during NKT cell development,
that mice lacking either factor are selectively
deficient in NKT cells (10–13). NKT cells are
detected wherever conventional T cells are
found, although their frequency relative to
other T cells is tissue dependent; the highest
NKT cell/T cell ratio is found in the liver
(14–17).
A striking characteristic of NKT cells is
their ability to produce Th1 (e.g., IFN-
 
 
 
 and
TNF) and Th2 type (e.g., IL-4 and -13) cy-
tokines rapidly upon primary stimulation. This
suggests an important and diverse role for these
cells in immunoregulation, although how one
cell type that produces Th1 and Th2 type
cytokines can direct an immune response
clearly is a major paradox in the NKT cell
field. Many studies in mouse models have
demonstrated that NKT cells can influence a
broad range of diseases, including autoimmune
diseases such as type 1 diabetes, graft-versus-
host disease, graft rejection, systemic suppression
of cell-mediated immunity after introduction
of antigen into the anterior chamber of the
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eye. They also contribute to airway hypersensitivity and
contact sensitivity in mice. These activities are generally
thought to be due to the production of type 2 cytokines, in-
cluding IL-4, -10, and -13, by NKT cells (for reviews see
references 18–21). In contrast to the studies that showed that
NKT cells can suppress cell-mediated immunity, many other
studies demonstrated that NKT cells also can promote po-
tent cell-mediated antitumor responses (e.g., rejection of
B16F10 melanoma) when stimulated with exogenous IL-12
or 
 
 
 
-GalCer (for review see reference 22). Even in the ab-
sence of exogenous stimulation, NKT cells are essential for
preventing the development and growth of MCA-induced
sarcomas (23). We demonstrated, with both tumor models,
that the defective tumor immunity that was observed in
NKT cell–deficient J
 
 
 
18
 
 
 
/
 
 
 
 mice was restored by adoptive
transfer of NKT cells that were isolated from the liver of WT
donor mice, and that this protection was dependent upon
IFN-
 
 
 
 production by the transferred NKT cells (24, 25).
In studies in which we used adoptive transfer to restore
NKT cell–mediated tumor rejection in J
 
 
 
18
 
 
 
/
 
 
 
 mice (24,
25), we used liver-derived NKT cells because of their rela-
tive abundance, and it was assumed that these were represen-
tative of all NKT cell populations in vivo. At least two phe-
notypically distinct subsets of NKT cells exist in the liver and
other tissues of mice, defined as CD4
 
 
 
CD8
 
 
 
 (CD4
 
 
 
) and
CD4
 
 
 
CD8
 
 
 
 double negative, and an additional CD4
 
 
 
CD8
 
 
 
 subset exists in humans (1). In vitro culture of CD4
 
 
 
and CD4
 
 
 
 NKT cells from mice or humans, and NKT cells
from various tissues in mice, revealed that NKT cell subsets
can behave differently, at least in terms of their cytokine pro-
duction in vitro (15, 26–30). Together, these studies raised
the intriguing possibility that NKT cell subsets may be dif-
ferentially responsible for the diverse functions that are at-
tributed to these cells in vivo
 
.
 
 We sought to test this hypoth-
esis by using adoptive transfer of various NKT cell subsets
into two distinct models of tumor immunity. Our results
provide the first evidence to directly demonstrate the exist-
ence of functionally distinct NKT cell subsets in vivo.
Whereas liver CD4
 
 
 
 NKT cells are capable of promoting
tumor rejection, other NKT cell subsets, including thymus
and spleen-derived NKT cells and liver-derived CD4
 
 
 
 NKT
cells, are far less potent in this capacity. Our results have far-
reaching implications for all studies that examine NKT cell
function, and indicate that care must be taken when NKT
cell subsets are being examined and manipulated.
 
RESULTS
Liver-derived NKT cells are unique in their ability to prevent 
MCA-1 sarcoma growth
 
We reported that NKT cell–deficient TCR J
 
 
 
18
 
 
 
/
 
 
 
 mice
were more susceptible to the development and growth of
MCA-induced sarcomas than WT mice (23). We also dem-
onstrated that protection against sarcoma growth was re-
stored to TCR J
 
 
 
18
 
 
 
/
 
 
 
 mice upon adoptive transfer of liver-
derived WT NKT cells (24) (Fig. 1 A). Liver-derived NKT
cells were used in these studies because of their relative abun-
dance, and it was assumed that these cells were functionally
representative of all NKT cell populations in vivo. To test
this hypothesis directly, NKT cells were isolated from the
liver, spleen, and thymus of WT mice and adoptively trans-
ferred into MCA-1–injected TCR J
 
 
 
18
 
 
 
/
 
 
 
 recipients. Con-
sistent with our earlier report (24), transfer of 2.5 
 
 
 
 10
 
5
 
liver-derived NKT cells into MCA-1–inoculated TCR
J
 
 
 
18
 
 
 
/
 
 
 
 mice induced complete inhibition of tumor growth
(Fig. 1 A). In contrast, the equivalent number of spleen- or
thymus-derived NKT cells from the same donor mice failed
Figure 1. Liver-derived NKT cells are optimal mediators of MCA-1 
tumor immunosurveillance. TCR J 18 /  mice were inoculated s.c. in 
the right hind flank with 105 MCA-1 cells. Groups of TCR J 18 /  mice 
then received sorted liver- (A), spleen- (B), or thymus-derived (C) NKT cells 
or, 2% NMS in PBS by way of i.v. injection. Sorted populations were always 
 94%,  91%, and  97% pure, respectively. Results were recorded every 
other day as the mean tumor size (cm2)   SEM. Data are pooled from 
three (A), one (B), and two (C) experiment(s) with three to five mice/group/
experiment. The number of mice in each group is indicated in parentheses. 
PBS-treated TCR J 18 /  control data are the same for A, B, and C and is 
shown for comparison. Significant difference in tumor growth rate was 
determined between the PBS-treated TCR J 18 /  control group and the 
mice that received liver, spleen, or thymus-derived NKT cells using a 
Kruskal-Wallis statistical test, followed by a Dunn’s post test. ***P   0.001. 
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to inhibit tumor growth (Fig. 1, B and C). In fact, even
twice as many (5 
 
 
 
 10
 
5
 
) thymus-derived NKT cells were
unable to restore protection (Fig. 1 C), which suggests that
liver NKT cells have unique functional characteristics that
are necessary for efficient rejection of the MCA-1 sarcoma.
 
Liver-derived CD4
 
 
 
, but not liver CD4
 
 
 
, NKT cells mediate 
tumor immune surveillance
 
Given that liver-derived NKT cells are unique in their abil-
ity to mediate MCA-1 rejection, we sought to determine
whether CD4
 
 
 
 and CD4
 
 
 
 subsets of liver-derived NKT cells
possessed this capacity. Each subset was sorted and adoptively
transferred into MCA-1–inoculated TCR J
 
 
 
18
 
 
 
/
 
 
 
 recipi-
ents. As shown in Fig. 2 A, CD4
 
 
 
 NKT cells completely re-
stored protection against MCA-1, whereas the equivalent
number of CD4
 
 
 
 NKT cells did not. At best, CD4
 
 
 
 NKT
cells slowed tumor growth when compared with PBS-
injected controls. Considering that CD4
 
 
 
 cells make up 
 
 
 
30%
of the liver-derived NKT cell population, and that the anti-
tumor effects resided primarily within this compartment, it
was hypothesized that a lower dose of these cells than that es-
tablished for unfractionated liver-derived NKT cells (2.5 
 
 
 
10
 
5
 
) (24), would still restore complete protection. MCA-1–
inoculated TCR J
 
 
 
18
 
 
 
/
 
 
 
 recipients were injected with a
range of CD4
 
 
 
 doses (2.5 
 
 
 
 10
 
5
 
, 10
 
5
 
, 5 
 
 
 
 10
 
4
 
 cells), and
were monitored for tumor development (Fig. 2 B). Restora-
tion of tumor rejection was dose dependent; 2.5 
 
 
 
 10
 
5
 
 and
10
 
5
 
 CD4
 
 
 
 cells completely inhibited tumor growth, while
5 
 
 
 
 10
 
4 cells considerably delayed tumor onset and progres-
sion. Given that CD4  NKT cells represent  30% of total
NKT cells in liver (unpublished data), the number of CD4 
cells required for complete tumor inhibition (105) was similar
to the number of these cells ( 0.8   105) present in the
minimum dose of unfractionated liver-derived NKT cells
(2.5   105) necessary for complete protection (24). This sup-
ports the concept that the CD4  subset is mostly, if not com-
pletely, responsible for the antitumor effects of liver-derived
NKT cells.
Survival of NKT cell subsets after adoptive transfer
One explanation for the lack of protection mediated by
thymus-derived NKT cells is that they might not survive
after transfer into the periphery. To address this possibility,
NKT cell–enriched thymocytes were carboxyfluorescein
diacetate succinimidyl ester (CFSE)–labeled and transferred
Figure 2. Liver-derived CD4  NKT cells are the most potent mediators 
of MCA-1 tumor immunosurveillance. TCR J 18 /  mice were inoculated 
s.c. in the right hind flank with 105 MCA-1 cells. Groups of TCR J 18 /  mice 
then received sorted CD4  or CD4  liver-derived NKT cells, or 2% NMS in 
PBS (A), or a range of liver-derived CD4  NKT cell doses (2.5   105, 105 or 5   
104 cells), by way of i.v. injection (B). Results were recorded every other day
as the mean tumor size (cm2)   SEM. Data are pooled from two independent 
experiments (A and B). We used three to five mice/group/experiment. The 
number of mice with measurable tumors over total mice per group is 
indicated in parentheses. PBS-treated TCR J 18 /  control data are the same 
for A and B, and are shown for comparison. Significant difference in tumor 
growth rate was determined between the PBS-treated control group and 
mice receiving CD4  NKT cells, using a Mann-Whitney U test. *P   0.05.
Figure 3. Thymus-derived NKT cells detected several days after 
transfer. NKT cell–enriched thymocytes were CFSE-labeled and transferred 
into WT recipients by way of i.v. injection (A, left). 6 d after transfer, organs 
were harvested and screened for the presence of CFSE CD1d/ -GalCer  
cells (A, right). These cells were gated on, and analyzed for, CD4 expression 
(B, middle and right). Some mice received CFSE-labeled cells that were labeled 
with anti-CD4 before transfer (B, right). Data are representative of six (A) or 
two (B) experiments with one or two mice/group.FUNCTIONALLY DISTINCT NKT CELL SUBSETS | Crowe et al. 1282
into WT recipients. 6 d later, organs were harvested and
analyzed for the presence of CFSE  CD1d/ -GalCer
tetramer  cells. These cells were clearly detected in liver
(Fig. 3 A), and to a lesser extent in spleen, PBLs, and BM
(not depicted) for at least a week after transfer. In other ex-
periments, we could detect clear populations of thymus-
derived NKT cells 8 weeks after adoptive transfer (unpub-
lished data). Transferred liver- and spleen-derived NKT
cells were also detectable in these tissues (albeit at a lower
rate relative to the number of NKT cells injected, which
was consistent with a previous report [31]) with a similar
tissue distribution (unpublished data). Another explanation
for the inability of CD4  NKT cells to confer complete tu-
mor inhibition is that CD4 labeling for FACS sorting may
induce the preferential depletion of this subset in vivo. To
address this possibility, mice received CFSE-labeled NKT
cells that were, or were not, labeled with anti-CD4 before
transfer. As shown in Fig. 3 B, prelabeled CD4  NKT cells
were detected at the same frequency as nonprelabeled
CD4  NKT cells 6 d after transfer, indicating that CD4 la-
beling did not affect survival of these cells.
Liver-derived NKT cells are predominant mediators 
of  -GalCer–induced antitumor immunity
One possible explanation for the differential responsiveness
of NKT cell subsets in these studies is that liver CD4  NKT
cells are activated selectively in response to the MCA-1 tu-
mor. Therefore, we used a model in which all NKT cells are
stimulated to test whether this distinction existed. We pre-
viously reported that adoptive transfer of liver-derived
NKT cells into  -GalCer–treated, B16F10-inoculated TCR
J 18 /  recipients inhibited B16F10 metastases in the lungs
(25). To determine whether spleen- and thymus-derived
NKT cells promoted similar antitumor immunity, unfrac-
tionated liver-derived lymphocytes, NKT cell–enriched thy-
mocytes, and splenocytes were adoptively transferred into
 -GalCer–treated, B16F10-inoculated, TCR J 18 /  mice.
Each transferred population contained 105 NKT cells, which
Figure 4. Liver-derived NKT cells are most efficient mediators of 
 -GalCer–induced antitumor immunity. TCR J 18 /  mice were 
inoculated with 5   105 B16F10 cells by way of i.v. injection. 3 h later, 
some mice received unfractionated liver-derived lymphocytes (A and B), 
NKT cell–enriched thymocytes or splenocytes, sorted thymus-derived 
NKT cells (A), or sorted liver- or thymus-derived CD4  or CD4  NKT cell 
subsets (B) by way of i.v. injection. On the same day as lymphocyte 
transfer, and again on days 4 and 8, some mice also received 2  g 
 -GalCer or vehicle by way of i.p. injection. 14 d after tumor inoculation, 
lungs were harvested, and B16F10 colonies were counted and recorded 
as the mean number   SEM. Data are pooled from two independent 
experiments and the total number of mice in each group is indicated in 
parentheses. Significant difference in tumor growth rate was determined 
between mice receiving NKT cells and vehicle, and mice receiving NKT 
cells and  -GalCer, using a Kruskal-Wallis test, followed by a Dunn’s 
post test. *P   0.05; **P   0.01; ***P   0.001.JEM VOL. 202, November 7, 2005 1283
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we determined previously to be a protective dose (25).
As expected, liver-derived NKT cells effectively inhibited
B16F10 metastases in the lungs (Fig. 4 A). However, consis-
tent with earlier findings from the MCA-1 model, spleen-
derived NKT cells were less effective than were liver-
derived NKT cells at reducing the number of metastases.
Even more striking was the inability of NKT cell–enriched
thymocytes or sorted thymus-derived NKT cells to inhibit
tumor metastases, even when a fivefold increase in NKT cell
dosage (5   105) was used (Fig. 4 A). In some experiments,
NKT cells were purified by FACS sorting based on NK1.1
versus   TCR expression from liver, spleen, and thymus,
with similar results.
Liver-derived CD4  NKT cells are the most potent mediators 
of  -GalCer–induced antitumor immunity
To determine whether CD4  and CD4  subsets of liver-
derived NKT cells were capable of mediating  -GalCer–
induced antitumor immunity, each subset was sorted and
adoptively transferred into  -GalCer–treated, B16F10-inoc-
ulated, TCR J 18 /  recipients (Fig. 4 B). Whereas both
subsets promoted  -GalCer–induced antitumor immunity,
this was mediated more potently by the CD4  subset. Sig-
nificant (P   0.01) antitumor activity was observed after
transfer of 2.5   104 CD4  NKT cells, whereas equivalent
numbers of CD4  NKT cells had little effect. For compari-
son, we also injected some mice with thymic NKT cells that
had been subdivided into CD4  and CD4  subsets (Fig. 4
B). As for unfractionated thymic NKT cells, neither CD4 
nor CD4  subsets showed enhanced protection.
We demonstrated previously that NKT cell–derived
IFN-  is critical for tumor immunosurveillance against
MCA-1 and  -GalCer–induced antitumor immunity against
B16F10 (24, 25). To investigate whether differences in IFN- 
production were responsible for the functional differences
that were observed, WT mice were injected with  -GalCer,
and CD4  and CD4  NKT cell subsets from the liver and
spleen were analyzed for their production of intracellular cy-
tokines. As shown in Fig. 5 A, no clear differences were ob-
served; all populations produced similar levels of IFN-  and
IL-4 after  -GalCer stimulation. Because thymic NKT cells
are not stimulated by  -GalCer in situ (16, 32), thymus- and
liver-derived NKT cells were isolated from naive mice and
stimulated in vitro with sorted spleen-derived DCs and 100
ng/ml  -GalCer for 12 h (Fig. 5 B). Intracellular cytokine
staining of these cells demonstrated that IFN-  and IL-4
production was similar between CD4  and CD4 , subsets
from the thymus and liver.
NKT cell–derived IL-4 production impairs antitumor 
function of thymus-derived NKT cells
To investigate whether IL-4 and/or IL-10 production an-
tagonizes the potential of some NKT cell subsets to con-
fer protection, NKT cells were enriched or purified from
the thymus and liver of WT and IL-4 /  mice and adop-
tively transferred into  -GalCer–treated, B16F10-inoculated,
Figure 5. Cytokine production by NKT cell subsets after  -GalCer 
stimulation. WT mice received 2  g  -GalCer or vehicle by way of i.p. injec-
tion and were killed 2 or 48 h later (A). Liver- and spleen-derived lymphocytes 
were cultured without further stimulation for 2 h in Brefeldin A. After culture, 
cells were labeled with surface mAb, fixed, and permeabilized for intracellular 
cytokine staining. Cells were analyzed by flow cytometry, and CD1d/
 -GalCer   TCR  cells were gated on and CD4  and CD4  subsets screened 
for intracellular IFN-  production. Gates were set based on the isotype control 
at each time point. (B) Liver lymphocytes and NKT cell–enriched thymocytes 
(with sorted spleen-derived DCs) were cultured for 12 h with 100 ng/ml 
 -GalCer. Brefeldin A was added for the final 2 h of culture. After culture, cells 
were prepared for intracellular cytokine staining (as for A). NK1.1   TCR  
cells from the liver and NK1.1  cells from the thymus were electronically gated 
and CD4  and CD4  subsets were analyzed for intracellular IFN-  production 
(filled line graph: DCs with  -GalCer; dotted line: nonstimulated control).FUNCTIONALLY DISTINCT NKT CELL SUBSETS | Crowe et al. 1284
TCR J 18 /  mice, some of which also were treated with a
neutralizing anti–IL-10 mAb. The activity of this batch of
mAb was confirmed by using an inhibition ELISA (unpub-
lished data) at two to four times the amount (400  g/mouse
on days 0, 4, and 8) known to effectively block IL-10 signal-
ing in other in vivo models (33–35). As shown in Fig. 6 A,
IL-4 /  liver-derived NKT cells were significantly (P  
0.05) more protective than were the same number of WT
liver-derived NKT cells. Furthermore, IL-4 /  thymus-
derived NKT cells also were able to protect in this model, in
sharp contrast to WT thymus-derived NKT cells. Neutraliz-
ing anti–IL-10 had little additional effect. One possible ex-
planation for the enhanced tumor immunity after transfer of
IL-4 /  cells was that in the absence of IL-4 production,
NKT cell–derived IFN-  production was enhanced. We
tested this by comparing IFN-  production by NKT cells in
IL-4 /  and WT mice after  -GalCer administration in
vivo. As shown in Fig. 6 B, IFN-  production was compara-
ble between CD4  and CD4  NKT cell subsets from each
strain 2 and 48 h after stimulation. Taken together, this
suggests that thymus-derived NKT cells are capable of re-
sponding to the tumor, but are unable to do so because IL-4
production antagonizes their ability to mediate IFN- –
dependent tumor rejection. How liver-derived NKT cells
inhibit tumor growth—despite similar levels of IL-4 produc-
tion to thymus-derived NKT cells—is unclear but might re-
late to other (undefined) cytokines that are expressed differ-
entially between these NKT cell subsets, or by differences in
their ability to transactivate NK cells and DCs. This latter
possibility was investigated using in vitro cultures in which
NKT cells from thymus or liver of WT mice were cocul-
tured for 12 h, in the presence of  -GalCer, with liver
mononuclear cells from J 18 /  mice (Fig. S1, available
at http://www.jem.org/cgi/content/full/jem.20050953/DC1).
This induced IFN-  production by NK cells, enhanced
CD69 expression by DCs and NK cells, and increased the
percentage of CD86  DCs. However, we found no obvious
difference in the ability of thymus- and liver-derived NKT
cells in this assay that would explain the differential antitumor
immunity observed.
DISCUSSION
We previously reported that adoptive transfer of liver-
derived NKT cells restores antitumor immunity to TCR
J 18 /  mice (24, 25). These and other studies presumed
that liver-derived NKT cells were a functionally homoge-
nous population that was representative of all NKT cells.
However, our current study demonstrates that liver NKT
cells, and primarily the CD4  subset, are unique in their
ability to confer protective antitumor responses. It is not
clear why spleen- and thymus-derived NKT cells do not
confer similar protective responses, but there are several
plausible explanations. We considered the possibility that
thymus-derived NKT cells are functionally less mature than
NKT cell populations that are found in the periphery. Yet
our data, and that of other investigators, clearly demonstrate
that thymus-derived NKT cells are potent cytokine produc-
ers after in vitro stimulation (15, 17, 36–39), and that these
cells survive in the periphery after adoptive transfer (31).
Furthermore, adoptive transfer of thymus- (40) or spleen-
derived (41) NKT cells into NOD mice conferred IL-4–
Figure 6. NKT cell–derived IL-4 production impairs antitumor 
function of thymus-derived NKT cells. (A) TCR J 18 /  mice were in-
oculated with 5   105 B16F10 cells by way of i.v. injection. 3 h later, some 
mice received unfractionated liver-derived lymphocytes, NKT cell–enriched 
thymocytes, or sorted liver- and thymus-derived NKT cells from WT and 
IL-4 /  donors by way of i.v. injection. For IL-10 neutralization, some mice 
received 400  g anti–IL-10 on the same day as lymphocyte transfer (day 0), 
and again on days 4 and 8 by way of i.p. injection. Some mice also received 
2  g  -GalCer or vehicle by way of i.p. injection on days 0, 4, and 8. 14 d 
after tumor inoculation, lungs were harvested, and B16F10 colonies were 
counted and recorded as the mean number   SEM. The number of mice in 
each group is indicated in parentheses. Results from mice receiving WT or 
IL-4 /  NKT cells from thymus or liver were compared using a Mann-Whitney 
rank sum test. *P   0.05. (B) WT and IL-4 /  mice received 2  g  -GalCer 
or vehicle by way of i.p. injection and were killed 2 or 48 h later. Liver-derived 
lymphocytes were cultured without further stimulation for 2 h in Brefeldin A, 
before being labeled with surface mAb, fixed, and permeabilized for 
intracellular cytokine staining. Cells were analyzed by flow cytometry and 
CD1d/ -GalCer   TCR  cells were electronically gated and analyzed for 
intracellular IFN-  production and CD4 expression.JEM VOL. 202, November 7, 2005 1285
ARTICLE
and/or IL-10–dependent suppression of type 1 diabetes,
which demonstrated that these cells can mediate effector
functions in vivo. Spleen-derived NKT cells are also clearly
functional because they can mediate anterior chamber-asso-
ciated immune deviation in an IL-10–dependent manner
(42), and can promote airway hyperresponsiveness by way of
IL-4 and -13 production (43); this further supports the idea
that they are not functionally immature. Clearly, thymus-
and spleen-derived NKT cells can influence immune re-
sponses upon adoptive transfer in vivo. This raises the possi-
bility that these cells are specifically less efficient at mediating
tumor rejection compared with liver-derived NKT cells,
and by definition, should be regarded as a functionally dis-
tinct subset. This has interesting implications for other stud-
ies that involve the adoptive transfer of liver-derived NKT
cells (e.g., references 44, 45), and raises several important
questions, such as whether the effects that are mediated by
NKT cells in these studies are also influenced by the NKT
cell tissue of origin. Considering that these responses ap-
peared to be dependent on NKT cell–derived IL-4 (i.e., the
opposite of our current study), this raises the question of
whether these functional roles also are unique to liver NKT
cells, and whether CD4  and CD4  subsets of liver NKT
cells contribute equally to the various diseases in which
NKT cells are known to play a role.
The ability of IL-4 /  thymus-derived NKT cells to re-
store  -GalCer–induced antitumor immunity supports the
idea that these cells are functionally active upon adoptive
transfer, and that they can recognize and respond to the tu-
mor, but that the production of IL-4 antagonizes their ability
to promote effective tumor rejection. These findings are
reminiscent of observations in a model of experimental au-
toimmune encephalomyelitis, in which the Th1-type disease
was heightened in IL-4 /  mice and was inhibited in IFN-
  /  mice after  -GalCer treatment (46).
This study is the first in vivo demonstration of function-
ally distinct NKT cell subsets in two disease models. In vitro
studies have reported differences in cytokine production be-
tween CD4  and CD4  NKT cell subsets from mice (15)
and humans (28, 30, 47, 48); however, the physiological sig-
nificance of these results is unclear and does not easily ex-
plain the differences in our study. We were unable to deter-
mine any clear differences in cytokine production that could
explain the functional disparity between CD4  and CD4 
liver NKT subsets. Both subsets produced similar levels of
IFN-  and IL-4 by cytokine staining, and were detected in
similar locations after adoptive transfer, including at the tu-
mor site (albeit in very low numbers) (unpublished data).
Further study of factors that are expressed differentially be-
tween NKT cell subpopulations is warranted.
Our results demonstrate the importance of studying dis-
tinct NKT cell subsets in the various models in which these
cells are involved. Specifically, the tissue of origin (e.g., liver,
thymus, or spleen) and the subset within that tissue (e.g.,
CD4  or CD4 ) needs to be considered because the use of
different subsets may influence results dramatically. It should
be emphasized that our study may not prove to be the most
complete breakdown of NKT cell subsets, and that addi-
tional ways to subdivide NKT cell populations, based on
their functional distinction, may become apparent. An at-
tractive hypothesis is that different NKT cell subsets have
different functional roles in vivo. Thus, CD4  liver-derived
NKT cells may be very efficient at promoting Th1-type cell-
mediated immunity, whereas other NKT cell subpopula-
tions, such as thymus-, spleen-, and liver-derived CD4 
NKT cells, might be more efficient at conferring immuno-
suppressive effects. This needs to be tested by comparing the
activity of these subsets in other models of NKT cell–depen-
dent immune responses that require a cell-mediated Th1-
like or immunosuppressive Th2-like effect. The ability to
separate potentially suppressive and/or aggressive NKT cell
subsets will be an important step forward for NKT cell re-
search, especially now that these cells are being targeted in
 -GalCer–based clinical trials. Global activation of NKT
cells by administration of soluble  -GalCer and/or  -Gal-
Cer–pulsed DCs could be detrimental because they may in-
duce opposing effects that reduce the efficiency of treatment
and/or cause undesirable effects. These could be eliminated
by targeting individual NKT cell subsets, which might be
achieved by in vitro isolation and stimulation of the desired
subset before transfer, or potentially by the targeted suppres-
sion of particular subsets in vivo. Future studies should also
aim to determine whether NKT cell subsets are precondi-
tioned in their relative environments before transfer, or
whether distinct functional capabilities are intrinsic to each
subset upon export from the thymus. Thus, the novel find-
ings that are reported in this study are likely to have major
implications for future studies that investigate the potential
of NKT cells in immunotherapy.
MATERIALS AND METHODS
Mice. Inbred C57BL/6 WT mice were bred in-house at the Department of
Microbiology and Immunology Animal House, Melbourne University, or
the Peter MacCallum Cancer Institute Animal House. TCR J 18 /  mice
(provided by M. Taniguchi, Chiba University Graduate School of Medicine,
Chiba, Japan and backcrossed to C57BL/6 for 12 generations) and C57BL/6
IL-4 /  mice (The Jackson Laboratory) were bred at the Peter MacCallum
Cancer Institute. Mice of 6–14 wk of age were used in all experiments that
were performed according to animal experimental committee guidelines.
Isolation of NKT cell subsets. Lymphocytes were isolated from the liver
by cutting it into small pieces and gently pressing it through 200- m mesh
sieves into PBS containing 2% FCS (Commonwealth Serum Laboratories).
Lymphocytes were separated from hepatocytes and cellular debris by way of a
33% isotonic Percoll density gradient (GE Healthcare) performed at room
temperature. Exposed DNA was removed using DNase (35  g/ml final con-
centration) (Roche Diagnostics). Lymphocytes were isolated from the thymus,
spleen, and LNs by cutting the organs and gently grinding them between two
frosted glass slides into PBS containing 2% FCS. BM was harvested by flushing
femurs with PBS containing 2% FCS. Blood was collected, by way of cardiac
puncture, into 10 ml of PBS to prevent clotting. Liver, spleen, BM, and PBLs
were depleted of RBCs using red cell lysis buffer (Sigma-Aldrich).
NKT cell enrichment. For thymus-derived NKT cell enrichment, thy-
mocytes were labeled with anti-CD8 (clone 3.155) and anti-CD24 (J11D)
(both grown in-house), and bound cells were depleted using rabbit comple-FUNCTIONALLY DISTINCT NKT CELL SUBSETS | Crowe et al. 1286
ment (C-six Diagnostics). Clumping of dead cells was avoided by using
DNase, and viable cells were collected using a histopaque (1.083 g/ml) gra-
dient (Sigma-Aldrich) performed at room temperature. Cells were washed
twice before being surface labeled for flow cytometric sorting. Spleen-
derived NKT cells were enriched by B cell depletion. This was achieved in
one of two ways in different experiments, either by incubating spleen cells
on 90-mm petri dishes that were coated with purified goat anti–mouse Ig
(15  g/ml; Caltag), or anti-B220 labeling followed by magnetic depletion
with anti-rat Ig–coated Dynabeads (Dynal). In an alternative enrichment
procedure, splenocytes were labeled with  -GalCer–loaded CD1d tetra-
mers (CD1d/ -GalCer) followed by anti-PE microbeads (Miltenyi Biotec).
Cells were passed through an automated magnetic cell sorter (autoMACS)
enrichment column (Miltenyi Biotec), and collected into PBS containing
2% FCS and 2 mM EDTA (Sigma-Aldrich).
Antibodies and flow cytometric cell sorting. For sorting of NKT cell
populations, unfractionated or NKT cell–enriched populations were labeled
with combinations of antibodies, including FITC-conjugated anti-  TCR
(clone H57-597), FITC-conjugated anti-CD4 (clone RM4-5), PE-conju-
gated anti-NK1.1 (clone PK-136), biotinylated anti-CD4 (clone RM4-5),
or allophycocyanin-conjugated anti-  TCR (clone H57-597). For DCs,
splenocytes were labeled with PE-conjugated anti-MHC class II (clone
M5/114.15.2) and biotinylated anti-CD11c (clone HL3). Biotinylated anti-
bodies were revealed using streptavidin-CyChrome. To avoid nonspecific
binding of antibodies to FcR- , cells were incubated with anti–mouse
CD16/32 (clone 2.4G2) (grown in-house). All flow cytometry reagents
were purchased from BD Biosciences unless otherwise indicated. After cell
surface labeling, cells were sorted using a FACStarPLUS (Becton Dickinson)
or MoFlow (DakoCytomation). Desired populations were collected into
2% normal mouse serum (NMS) in PBS. A sample of sorted cells was always
analyzed to assess the purity of these populations. Sorted NK1.1   TCR 
(NKT cell) populations were always  95% pure, and CD4high (CD4 )
and CD4 /low (CD4 ) NKT cell subsets were always  96% pure, unless
otherwise indicated.
Culture media. Culture media contained RPMI 1640 (GIBCO BRL)
supplemented with 5% FCS (JRH), 100 U/ml penicillin (GIBCO BRL), 100
 g/ml streptomycin (GIBCO BRL), and 2 mM Glutamax (GIBCO BRL).
Intracellular cytokine staining after in vivo and in vitro  -GalCer
stimulation. For in vivo stimulation, WT or IL-4 /  mice received 2  g
 -GalCer or vehicle by way of i.p. injection, and were killed 2 or 48 h
later. Lymphocytes were isolated from the liver and spleen and cultured for
2 h, without further stimulation, in 5  g/ml Brefeldin A (Sigma-Aldrich).
For in vitro stimulation, NKT cell–enriched thymocytes or unfractionated
liver-derived lymphocytes were cultured for 12 h with sorted spleen-
derived DCs and 100 ng/ml  -GalCer in culture media (Life Technolo-
gies). Brefeldin A was added for the last 2 h of culture. After culture, in vivo
and in vitro stimulated cells were labeled with combinations of cell surface
antibodies, including FITC-conjugated anti-CD4 (clone RM4-5), Cy-
Chrome-conjugated CD1d/ -GalCer tetramer (produced in-house),
PerCP-conjugated anti-CD4 (clone RM4-5), and allophycocyanin-conju-
gated anti-  TCR (clone H57-597). Following cell surface labeling, cells
were washed once in PBS, and fixed in 0.5% paraformaldehyde in PBS
(BDH Chemicals) for 30–45 min in the dark at room temperature. Cells
were washed twice in PBS and incubated for 1 h in the dark at room tem-
perature with PE-conjugated anti–IFN-  (clone XMG1.2), anti-IL-4
(clone 11B11), or rat IgG1 (clone R3-34 as an isotype control) in 0.05% sa-
ponin (Sigma-Aldrich) in 5% FCS in PBS.
MCA-1 subcutaneous sarcoma model. The MCA-1 sarcoma cell line
was derived from a TCR J 18 /  mouse injected with 100  g MCA and
maintained as described previously (23). For growth of MCA-1, WT and
TCR J 18 /  mice were injected s.c. in the right hind flank with 105 sar-
coma cells. From 1–2 h later, subgroups of TCR J 18 /  recipient mice
received one of the following populations of cells from WT donors by way
of i.v. injection: unfractionated liver-derived lymphocytes; sorted liver-,
spleen-, or thymus-derived NK1.1   TCR  cells; sorted liver-derived
CD4  or CD4  NKT cell subsets; or 2% NMS in PBS. Tumor growth was
measured every second day with a caliper square as the product of two di-
ameters. Results were recorded as the mean tumor size (cm2)   SEM.
B16F10 lung metastases model. B16F10 melanoma cells were main-
tained as described previously (25). WT or TCR J 18 /  mice received
5   105 B16F10 cells by way of i.v. injection. 3 h later, some TCR J 18 / 
recipient mice received one of the following populations from WT donors
by way of i.v. injection, unless otherwise indicated: unfractionated liver-
derived lymphocytes, NKT cell–enriched thymocytes or splenocytes, sorted
thymus-derived NK1.1   TCR  cells, sorted liver- and thymus-derived
CD4  or CD4  NKT cell subsets, or 2% NMS in PBS. 1–2 h after lym-
phocyte transfer, and again on days 4 and 8, mice also received 2  g  -Gal-
Cer (provided by Kirin Breweries Pharmaceutical Research Laboratories,
Gunma, Japan, that was prepared in saline supplemented with 0.5% polysor-
bate-20). For IL-10 neutralization, some mice also were treated with 400
 g anti–IL-10 (clone JES-2A5) or control IgG on days 0, 4, and 8. Mice
were killed on day 14, and surface lung metastases were counted with the
aid of a dissecting microscope as described previously (49). Data were
recorded as the mean number of metastases   SEM.
In vivo detection of adoptively transferred NKT cells. NKT cell–
enriched thymocytes were washed once in 0.1% BSA in PBS, before being
labeled in 1 ml 0.1% BSA in PBS with 4  l of 1 mM 5-(and-6)-CFSE (In-
vitrogen) for 10 min at 37 C in the dark. The reaction was quenched with
PBS containing 20% FCS before cells were washed twice in RPMI 1640
and once in PBS, and transferred into recipient mice by way of i.v. injec-
tion. In some experiments, cells were labeled with anti-CD4 before trans-
fer. Organs (liver, spleen, PBLs, BM, LNs, and thymus) were harvested 6 d
after transfer, and screened by flow cytometry for the presence of CFSE 
cells. CFSE  cells were analyzed for CD1d/ -GalCer tetramer-binding,
  TCR, and CD4 expression.
Statistical tests. Significant differences in tumor growth rate between
PBS/vehicle-injected TCR J 18 /  control groups and multiple test
groups were determined using a Kruskal-Wallis test, followed by a Dunn’s
post test. Significant differences between vehicle-injected TCR J 18 / 
control groups and a single test group were determined using a Mann-
Whitney U test.
Online supplemental material. Fig. S1 shows that thymus, spleen, and
liver NKT cells induce similar amounts of bystander cell activation. Online
supplemental material is available at http://www.jem.org/cgi/content/full/
jem.20050953/DC1.
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